Comparative Pharmacology
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PREVACID NAPRAPAC 375 COPACKAGED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANTOPRAZOLE SODIUM versus PREVACID NAPRAPAC 375 COPACKAGED.
PANTOPRAZOLE SODIUM vs PREVACID NAPRAPAC 375 (COPACKAGED)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Proton pump inhibitor. Suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
Lansoprazole, a proton pump inhibitor, suppresses gastric acid secretion by inhibiting the gastric H+/K+-ATPase at the secretory surface of the gastric parietal cell. Naproxen, a nonsteroidal anti-inflammatory drug, inhibits cyclooxygenase (COX-1 and COX-2) reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
40 mg orally once daily for 8 weeks for erosive esophagitis; 40 mg intravenously once daily for 7-10 days for GERD with esophagitis.
One tablet (naproxen 375 mg / lansoprazole 15 mg) orally twice daily.
None Documented
None Documented
Terminal elimination half-life: ~1 hour (range 0.5–2 h); clinically, acid suppression lasts longer due to covalent binding to proton pumps
Naproxen: 12-17 hours (mean 14 hours); allows twice-daily dosing. Lansoprazole: 1.5-2 hours (fast metabolizers) to 3-4 hours (slow metabolizers); clinically negligible due to irreversibly binding to proton pumps.
Renal: ~71% as metabolites; fecal: ~18% via bile; unchanged renal excretion: <1%
Naproxen: Approximately 95% excreted in urine as unchanged naproxen (10%) and metabolites (~60% 6-O-desmethylnaproxen and conjugates); <5% in feces. Lansoprazole: Primarily metabolized in liver; metabolites excreted in urine (14-23%) and feces (~22%).
Category A/B
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor/NSAID Combination